University of Oklahoma College of Medicine | Strategic Alliance Partners

“I think having the ability to monitor patients with imaging and using things like PSMA-PET is good, but yet we're we sometimes have pitfalls with PSMA-PET too,” says Michael Cookson, MD.

"The landscape of prostate cancer management has evolved significantly over the past 30 years, with [active surveillance], advances in imaging and genetics, and improvements in the treatment of high-risk disease marking key areas of progress," writes Michael S. Cookson, MD, MMHC.

"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.

"The primary aim is looking at the dose-limiting toxicity of this drug combination," says Kelly L. Stratton, MD, FACS.

“This study really bridges the gap between STAMPEDE and PROTEUS and provides the opportunity for patients to get either surgery or radiation therapy,” says Kelly L. Stratton, MD, FACS.

"Unique to this study is that we'll be using Orgovyx," says Kelly L. Stratton, MD, FACS.

Michael S. Cookson, MD, MMHC, FACS, recaps several presentations on prostate cancer from the 2024 American Urological Association Annual Meeting in San Antonio, Texas.

"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.

"I predict 2024 will be a banner year for progress in the management of [NMIBC], and not only will we be moving the needle but also turning up the volume in this historically quiet space," writes Michael S. Cookson, MD, MMHC, FACS.

Kelly L. Stratton, MD, FACS, highlights 5 noteworthy prostate cancer abstracts set to be presented at the 24th Annual Meeting of the Society of Urologic Oncology.

The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.

"Keeping up-to-date is challenging, and rapid progress that is now occurring in our field is truly amazing," writes Michael S. Cookson, MD, MMHC, FACS.

"ctDNA holds a unique position as it offers a molecular means to quantify the extent of residual disease burden," says Adanma Ayanambakkam, MD.

"If a patient begins treatment with platinum-based chemotherapy and maintenance immune checkpoint inhibition, second-line options may involve evaluating erdafitinib, ADCs, or participation in clinical trials," says Adanma Ayanambakkam, MD.

An exclusive Urology Times survey measured US-based urologists’ uptake, access to, and indications for utilizing prostate-specific membrane antigen-targeting agents.

"Despite challenges, ongoing research and advancements in risk stratification, imaging techniques, and targeted therapies are paving the way for personalized and precision medicine approaches in prostate cancer management," writes Michael S. Cookson, MD, MMHC, FACS.

Kelly L. Stratton, MD, FACS, recaps several presentations on prostate cancer from the 2023 American Urological Association Annual Meeting in Chicago, Illinois.

"We anticipate that in the next decade, breakthroughs in genetic profiling of tumors for precision therapies will further reduce suffering and death from bladder cancer," writes Michael S. Cookson, MD, MMHC.

Michael S. Cookson, MD, MMHC, highlights 5 studies in prostate cancer being presented at the 2023 American Urological Association Annual Meeting.

Urologists weigh in on the challenges associated with whether, when, and how to treat these patients with prostate cancer.

"AI has...been increasingly utilized in the field of medicine, including cancer research, because of its potential to improve diagnostic accuracy, prognosis prediction, and personalized treatment planning," writes Michael S. Cookson, MD, MMHC.

"This trial did not require a biomarker for entry in, so patients were treated with combination therapy or standard care, which would have been the abiraterone alone, to see if there was a benefit," says Michael S. Cookson, MD, MMHC.

“We need to do better, and men in America deserve a better chance at long-term, good outcomes from their prostate cancer discovery,” says Michael S. Cookson, MD, MMHC.

"We are...entering a new era for patients with urologic malignancies. Furthermore, we are expanding our reach and influence in patient care designed to improve outcomes," writes Michael S. Cookson, MD, MMHC.

“The takeaway from that talk was that it's critically important to review drug plan options, particularly if the patient's on a high-cost drug,” says Kelly L. Stratton, MD, FACS.

“[The 2022 Huggins Medal Lecture from Harry Herr, MD] was a fascinating talk, and something that I think anyone could learn from,” says Kelly L. Stratton, MD, FACS.

“I think [it was a] great opportunity to catch up on what is going on with PSMA-PET and theranostics and then also understand that that landscape will change over the near future,” says Kelly L. Stratton, MD, FACS.

“It's very interesting to see how this continues to progress as a field,” says Kelly L. Stratton, MD FACS.

"Cancer doesn’t take a holiday or vacation, and it doesn’t care about a pandemic. Our efforts to reduce deaths from prostate cancer through screening and early detection must continue," writes Michael S. Cookson, MD, MMHC.